Residual risk in statin-treated patients

Future therapeutic options

Catherine Y. Campbell, Juan J. Rivera, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.

Original languageEnglish (US)
Pages (from-to)499-505
Number of pages7
JournalCurrent Cardiology Reports
Volume9
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
HDL Cholesterol
Coronary Disease
Cholesterol
Therapeutics
Angiotensin Receptor Antagonists
Platelet Aggregation Inhibitors
Risk Reduction Behavior
Angiotensin-Converting Enzyme Inhibitors
Life Style
Comorbidity
Diabetes Mellitus
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Residual risk in statin-treated patients : Future therapeutic options. / Campbell, Catherine Y.; Rivera, Juan J.; Blumenthal, Roger S.

In: Current Cardiology Reports, Vol. 9, No. 6, 11.2007, p. 499-505.

Research output: Contribution to journalArticle

Campbell, Catherine Y. ; Rivera, Juan J. ; Blumenthal, Roger S. / Residual risk in statin-treated patients : Future therapeutic options. In: Current Cardiology Reports. 2007 ; Vol. 9, No. 6. pp. 499-505.
@article{ebc60d11d0f342a699592efe596ae970,
title = "Residual risk in statin-treated patients: Future therapeutic options",
abstract = "Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.",
author = "Campbell, {Catherine Y.} and Rivera, {Juan J.} and Blumenthal, {Roger S}",
year = "2007",
month = "11",
doi = "10.1007/BF02938395",
language = "English (US)",
volume = "9",
pages = "499--505",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Residual risk in statin-treated patients

T2 - Future therapeutic options

AU - Campbell, Catherine Y.

AU - Rivera, Juan J.

AU - Blumenthal, Roger S

PY - 2007/11

Y1 - 2007/11

N2 - Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.

AB - Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.

UR - http://www.scopus.com/inward/record.url?scp=36049026764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049026764&partnerID=8YFLogxK

U2 - 10.1007/BF02938395

DO - 10.1007/BF02938395

M3 - Article

VL - 9

SP - 499

EP - 505

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

ER -